{"id":10803,"date":"2022-08-05T12:45:00","date_gmt":"2022-08-05T12:45:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/3837433_HK37433_0"},"modified":"2022-08-05T12:45:00","modified_gmt":"2022-08-05T12:45:00","slug":"united-biopharmas-study-reveals-new-class-of-monoclonal-antibody-for-effective-relief-of-urticaria-symptoms","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=10803","title":{"rendered":"United BioPharma’s Study Reveals New Class of Monoclonal Antibody for Effective Relief of Urticaria Symptoms"},"content":{"rendered":"
\n

New results demonstrate a newer class of anti-IgE antibody, UB-221, with superior neutralization, synthesis reduction, and durable relief in targeting allergic diseases<\/b> <\/p>\n

TAIPEI<\/span><\/span>, Aug. 5, 2022<\/span><\/span> \/PRNewswire\/ — United BioPharma (UBP) today announced their latest results featuring unprecedented and unique functional characteristics of UB-221 monoclonal antibody in the phase I single-dose clinical trial, with chronic spontaneous urticaria (CSU) patients, to exhibit durable disease symptom relief. The results were published in the latest Journal of Clinical Investigation (JCI)<\/a>.  <\/p>\n

A New Treatment Option for CSU<\/b><\/p>\n

The chronic spontaneous urticaria (CSU) has known to be caused by a type of protein or antibodies produced by the immune system, known as Immunoglobulin E (IgE).<\/p>\n

While the existing approved CSU therapy (omalizumab; Xolair\u00ae<\/span> <\/sup>) and investigational drug (ligelizumab), have exerted positive reaction to reduce the disease symptoms over the last two decades, United BioPharma’s latest results have shown that the potential of a newer class of anti-IgE monoclonal antibody UB-221 has superior efficacy in CSU and can prolong the suppression of the disease symptoms.     <\/p>\n

In the study, UB-221 has proven to be a potent IgE neutralizer and a significant inhibitor of IgE neo-synthesis. Meaning, UB-221 binds IgE with a higher affinity and inhibits IgE production at a far greater scale in comparison with other anti-IgE antibodies like omalizumab and ligelizumab.  <\/p>\n

The study also suggests this new class of monoclonal antibody shows promise for the prevention of the development of allergic symptoms, through targeting both high-affinity IgE receptor (Fc\u03f5RI) and low affinity IgE receptor (CD23) pathways.  <\/p>\n

In addition, a notable observation of the study is that UB-221 in free form can interact unrestricted with CD23. This unprecedented feature not found in any other anti-IgE antibodies, supports the contention that it could be of benefit to target IgE toward the non-inflammatory CD23 pathway. In other words, UB-221 can down-regulate IgE production and reduce serum IgE levels in urticaria patients.<\/p>\n

Other findings highlighted from the data published in the JCI include:  <\/p>\n